每經AI快訊，9月9日(ri)，中源協和(600645.SH)公(gong)告(gao)稱，公(gong)司(si)全資子公(gong)司(si)武漢光(guang)谷中源藥(yao)(yao)業(ye)有限公(gong)司(si)于(yu)(yu)2025年9月9日(ri)收到國家藥(yao)(yao)品監督(du)管(guan)理局核準簽發的(de)關于(yu)(yu)VUM02注射(she)液用(yong)于(yu)(yu)治療(liao)重(zhong)型(xing)(xing)(xing)(xing)/危(wei)重(zhong)型(xing)(xing)(xing)(xing)肺炎(yan)的(de)《藥(yao)(yao)物臨(lin)床(chuang)試驗批準通知書(shu)》。VUM02注射(she)液是中源協和自主研發的(de)冷凍保存型(xing)(xing)(xing)(xing)細胞(bao)制劑，臨(lin)床(chuang)擬用(yong)適應(ying)癥(zheng)增加(jia)重(zhong)型(xing)(xing)(xing)(xing)/危(wei)重(zhong)型(xing)(xing)(xing)(xing)肺炎(yan)的(de)治療(liao)。截至本公(gong)告(gao)日(ri)，全球尚未有用(yong)于(yu)(yu)治療(liao)重(zhong)型(xing)(xing)(xing)(xing)/危(wei)重(zhong)型(xing)(xing)(xing)(xing)肺炎(yan)的(de)同類細胞(bao)藥(yao)(yao)物上市，研發進展最(zui)快的(de)同類藥(yao)(yao)物處于(yu)(yu)臨(lin)床(chuang)試驗階段。